Search results
Added:
1 year ago
ESC 22 - In this short interview filmed onsite at ESC Congress 2022, Dr Douglas Bradley (University of Toronto, Toronto, CA) discusses the findings of the ADVENT-HF Trial (NCT01128816).
ADVENT-HF was designed to determine if a respiratory device, Adaptive Servo Ventilation can reduce the risk of cardiovascular hospitalisations and death in patients with heart failure and sleep apnoea. 732…
View more
Added:
3 years ago
Cardiovascular disease (CVD) is the leading cause of death worldwide. In the US, for example, CVD kills more men than the next seven causes of death combined, and more women than the next 16 causes of death combined.1 Some of the most dreaded effects of CVD result from atherosclerotic coronary artery disease (CAD) and its sequelae, including chronic angina, acute myocardial infarction (MI), heart…
View more
Added:
5 months ago
AHA 2023 — Investigators of ORBITA-2 trial, Dr Rasha Al-Lamee and Dr Christopher Rajkumar (Imperial College London, UK) talked with CardioNerds Ambassador, Dr Nazli Okumus about the randomised, placebo-controlled trial (NCT03742050) that compared the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy at 12 weeks.The ORBITA…
View more
Added:
3 years ago
Major advances in heart failure (HF) management have been achieved over the past three decades, yet it remains a syndrome with high morbidity and mortality, poor quality of life and high healthcare costs. Despite all advances in medical/device therapy, many HF patients continue to deteriorate, leading to poor quality of life and high rehospitalisation and mortality rates.1 The recent European…
View more
Added:
3 years ago
With the continuous growth of computer networks in hospitals and, more importantly, the possibilities for contacting other hospitals and healthcare providers by high-speed internet, plus the demand for faster diagnosis and cost-reductions, the interest for tele-medicine is increasing. The definition of tele-cardiology is: “the use of cardiovascular information exchanged from one site to another…
View more
Added:
3 years ago
Atrial fibrillation (AF) and heart failure (HF) are two disease conditions that are intimately intertwined, both pathophysiologically and clinically. Currently, over 2.3 million people in North America and 4.5 million in the EU have AF, making it the most common arrhythmia encountered in clinical practice.1,2 It is expected that by 2050 there will be over 10 million people with AF.3 The estimated…
View more
Added:
3 years ago
Although cardiovascular mortality has declined progressively in developed countries, ischaemic heart disease (IHD) and chronic stable angina cause a worse prognosis and poor quality of life and can dramatically increase healthcare costs.1–4 Traditionally, chronic stable angina has been interpreted as reversible episodes of myocardial ischaemia due to the presence of coronary artery disease…
View more
HFA 2023: Late-Breaking Science Video Collection
Video Series
Added:
3 years ago
Cardiovascular disease (CVD) is the leading cause of death worldwide. In the US, for example, CVD kills more men than the next seven causes of death combined, and more women than the next 16 causes of death combined. Some of the most dreaded effects of CVD result from atherosclerotic coronary artery disease (CAD) and its sequelae, including chronic angina, acute myocardial infarction (MI), heart…
View more
Added:
1 year ago
EHRA 2023 — Investigator, Prof Nicolas Doll (Schuechtermann-Klinik, DE) joins us to discuss the take-home messages from the international prospective randomised multi-centre CEASE-AF study (NCT02695277).
In a randomized controlled trial, 146 patients were enrolled to compare the safety, efficacy, and quality of life outcomes of a combined epicardial surgical plus endocardial catheter technique…
View more
« First